NAT2 and colorectal carcinoma: Given that ~ 21% of colorectal tumors undergo LOH at 8p2223, we estimate that ~ 79,000 individuals heterozygous for a NAT2 slow allele could potentially be eligible for therapy every year (given an annual incidence of 1.3 million CRC cases) (Supplementary Table 1).